Home › Research › Biomarkers
Association of Enlarged Perivascular Spaces With Early Serum and Neuroimaging Biomarkers of Alzheimer Disease Pathology
Ong JJH, Leow YJ, Qiu B, Tanato P, Zailan FZ, Sandhu GK, Kandiah N.. Neurology, 2025-08-22
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background and objectives Enlarged perivascular spaces (EPVS), recognized as a key feature of cerebral small vessel disease (CSVD), have emerged as a promising biomarker for vascular contribution to Alzheimer disease (AD) and other neurodegenerative diseases. Although previous studies have linked EPVS to cerebrovascular dysfunction, their relationship with AD pathology and cognitive decline remains underexplored, particularly in multiethnic cohorts. This study investigates the associations between basal ganglia EPVS burden, blood-based biomarkers (BBM), and cognitive outcomes in a Southeast Asian cohort. Methods This cross-sectional study drew from the Biomarkers and Cognition Study, Singapore, comprising participants recruited from the community, at Dementia Research Centre (Singapore) from 2022 to 2024. Participants underwent comprehensive neuropsychologic assessments and were classified into cognitively normal, subjective cognitive decline, and mild cognitive impairment (MCI) groups according to established diagnostic criteria. BBM including amyloid β oligomers, amyloid β42 (Aβ42) and β40 (Aβ40), phosphorylated tau 181 (p-tau181), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) were quantified. MRI Markers of CSVD (EPVS, white matter hyperintensities [WMH], lacunes, and microbleeds) were visually rated using validated scales. Associations between EPVS, biomarkers, and cognitive outcomes were analyzed using correlation or multivariable regression models adjusting for age, sex, education, cognitive diagnosis, and APOE ε4 carrier status. Results A total of 979 participants were included (mean age: 58.2 ± 10.7 years; mean education: 14.9 ± 3.5 years; 60.7% female). Elevated EPVS burden was positively correlated with higher GFAP (ρ = 0.166, 95% CI 0.104 to 0.228, p p p p p = 0.035). In addition, higher EPVS burden was linked to poorer visuospatial skills and executive function (Block Design Test, OR 0.182, 95% CI 0.037 to 0.890, p = 0.035). Discussion These findings suggest EPVS burden to be a potential marker of both CSVD and AD-related BBM pathology. The results support the potential of incorporating EPVS assessments into routine MRI evaluations to enhance early detection and risk stratification in AD. Longitudinal studies are needed to confirm the prognostic value of EPVS and to clarify mechanisms linking vascular dysfunction to amyloid and tau pathology.
What this study adds
Evidence grade: Moderate
This is a cross-sectional study of 979 participants. In 979 participants, a greater burden of enlarged perivascular spaces was linked to blood biomarkers of Alzheimer-related pathology and small vessel disease. Reported effect size: 60.7%; OR 0.182.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Ong, J. J. H., Leow, Y. J., Qiu, B., Tanato, P., Zailan, F. Z., Sandhu, G. K., et al. (2025). Association of Enlarged Perivascular Spaces With Early Serum and Neuroimaging Biomarkers of Alzheimer Disease Pathology. Neurology. https://doi.org/10.1212/wnl.0000000000213836
Vancouver
Ong JJH, Leow YJ, Qiu B, Tanato P, Zailan FZ, Sandhu GK, et al. Association of Enlarged Perivascular Spaces With Early Serum and Neuroimaging Biomarkers of Alzheimer Disease Pathology. Neurology. 2025. doi:10.1212/wnl.0000000000213836. PMID: 40845262.
BibTeX
@article{ong2025-40845262,
author = {Ong, J. J. H. and Leow, Y. J. and Qiu, B. and Tanato, P. and Zailan, F. Z. and Sandhu, G. K. and Kandiah, N.},
title = {{Association of Enlarged Perivascular Spaces With Early Serum and Neuroimaging Biomarkers of Alzheimer Disease Pathology}},
journal = {Neurology},
year = {2025},
doi = {10.1212/wnl.0000000000213836},
pmid = {40845262},
url = {https://doi.org/10.1212/wnl.0000000000213836}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Results A total of 979 participants were included (mean age: 58.2 ± 10.7 years; mean education: 14.9 ± 3.5 years; 60.7% female).
- Discussion These findings suggest EPVS burden to be a potential marker of both CSVD and AD-related BBM pathology.
- The results support the potential of incorporating EPVS assessments into routine MRI evaluations to enhance early detection and risk stratification in AD.
Why it matters
In 979 participants, a greater burden of enlarged perivascular spaces was linked to blood biomarkers of Alzheimer-related pathology and small vessel disease. This is a cross-sectional study, so it cannot show cause and effect or that acting on these findings prevents or treats Alzheimer's disease.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designcross-sectional
- Participants979
- Effect size60.7%; OR 0.182
- Evidence strengthModerate
How this study scored 58/100
Published in a leading specialty journal, and it is a snapshot of people at one point in time. Scored zero for randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 979 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 12 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 4.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 7.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 12 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Nagaendran Kandiah: h-index 45 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Nanyang Technological University: institution h-index 981 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40845262) |
| Free to read | 2 / 2 | Free to read |
| Total | 58 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Biomarkers from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.